|
|
Article: MERSANA REPORTS PRELIMINARY PHASE 1 RESULTS OF XMT-1001.(Financial report)
- Article from:
- AsiaPulse News
- Article date:
- June 5, 2009
CopyrightCOPYRIGHT 2009 Asia Pulse Pty Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MEDIA RELEASE PR34867
(Full text of statement. Contact details below.)
Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with - Pharmacokinetics and Prolonged Stable Disease in Refractory Tumors - Show Fleximer(R) Conjugated Drug Is Well Tolerated with Favorable Results Presented at American Society of Clinical Oncology (ASCO) Meeting
CAMBRIDGE, Mass., June 2 /PRNewswire-AsiaNet/ -- Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. XMT-1001 is ...
Related newspaper, magazine, and journal articles:
|
|
Article: Mersana Therapeutics, Inc. Appoints Chief ...
PR Newswire Europe;
February 12, 2008 ;
700+ words
... ... our second product, XMT-1107, will be significant ... Vancouver, Canada. About Mersana Therapeutics, Inc. Mersana, a ... s pipeline includes XMT-1001, a Fleximer ... is a trademark of Mersana Therapeutics, Inc. Pete Leone ...
|
|